[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-340514-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-340514-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","identification-of-vista-regulators-in-macrophages-mediating-cancer-cell-survival","Identification of VISTA regulators in macrophages mediating cancer cell survival","","Numerous human cancers evade immune checkpoint blockade through immune-suppressive macrophages that weaken antitumor immunity in the tumor microenvironment. The study elucidates a strategy to shift macrophages into a proinflammatory state by down-regulating VISTA via inhibition of AhR and IRAK1. A high-throughput microfluidic platform with a genome-wide CRISPR knockout screen identified regulators of VISTA levels. Knockdown reduced VISTA surface expression and sustained an antitumor phenotype, while dual targeting of AhR and IRAK1 in mice overcame ICB resistance with increased CD8+ and NK infiltration.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/identification-of-vista-regulators-in-macrophages-mediating-cancer-cell-survival/340514/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/identification-of-vista-regulators-in-macrophages-mediating-cancer-cell-survival/340514.png","ImageObject",300,407,{"name":42,"@type":43},"Evangeline","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How does VISTA contribute to immune checkpoint blockade resistance in cancer?","Question",{"text":63,"@type":64},"VISTA is expressed on myeloid cells in the tumor microenvironment and supports an anti-inflammatory, protumor phenotype, which impedes antitumor immune effector responses.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What approach was used to identify regulators of VISTA levels?",{"text":68,"@type":64},"A high-throughput microfluidic platform combined with a genome-wide CRISPR knockout screen was used to identify regulators controlling VISTA levels in macrophages.",{"name":70,"@type":61,"acceptedAnswer":71},"What was the effect of targeting AhR and IRAK1 on tumor response?",{"text":72,"@type":64},"In mouse models, targeting both AhR and IRAK1 overcame resistance to immune checkpoint blockade and increased infiltration of cytotoxic CD8+ cells, natural killer cells, and antitumor macrophages.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},340514,1790887826,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},13056703019662,"https://ap-avatar.wpscdn.com/avatar/be000253a8e92610077?_k=1778726343310543188","CANCER  \nIdentification of VISTA regulators in macrophages mediating cancer cell survival  \nAbdalla M. Abdrabou1,2,3, Sharif U. Ahmed4, Mengqi Jonathan Fan2, Bill T. V. Duong5, Kangfu Chen4, Pei-Ying Lo4, Julia M. Mayes2, Fatemeh Esmaeili2,6, Amin GhavamiNejad4, Hossein Zargartalebi2,4, Randy Singh Atwal1, Sichun Lin7,  \nStephane Angers5,7,8, Shana O. Kelley1,2,3,4,5,6*  \nNumerous human cancers have exhibited the ability to elude immune checkpoint blockade (ICB) therapies. This type of resistance can be mediated by immune-suppressive macrophages that limit antitumor immunity in the tumor microenvironment (TME). Here, we elucidate a strategy to shift macrophages into a proinflammatory state that down-regulates V domain immunoglobulin suppressor of T cell activation (VISTA) via inhibiting AhR and IRAK1. We used a high-throughput microfluidic platform combined with a genome-wide CRISPR knockout screen to identify regulators of VISTA levels. Functional characterization showed that the knockdown of these hits diminished VISTA surface levels on macrophages and sustained an antitumor phenotype. Furthermore, targeting of both AhR and IRAK1 in mouse models overcame resistance to ICB treatment. Tumor immunophenotyping indicated that infiltration of cytotoxic CD8+ cells, natural killer cells, and antitumor macrophages was substantially increased in treated mice. Collectively, AhR and IRAK1 are implicated as regulators of VISTA that coordinate a multifaceted barrier to antitumor immune responses.  \ncopyright © 2024 the Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S.  \nGovernment Works. distributed under a creative commons Attribution Noncommercial license 4.0 (cc BY-Nc) .  \nINTRODUCTION  \nWhile immune checkpoint therapies (ICT) are known to elicit T cell responses in the realm of oncology, their success remains limited toa small fraction of patients, and they are not universally effective against all types of cancer (1, 2) . It is therefore critical to understand the mechanisms driving adaptive resistance to these therapies and explore strategies to overcome them. Adaptive resistance in the context of immunotherapy can arise through various mechanisms (3) . One key feature of adaptive resistance is the suppressive tumor microenvironment (TME) that plays a notable role in augmenting tumor survival, driven by the presence of protumor tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (4) . Another contributing factor is low mutational burden, which leads to an insufficient presentation of neoantigens on “cold” tumors and insufficient activation ofT cell response (5) .  \nTAMs orchestrate the communication between T cells and tumor cells in the TME. However, they can represent a major impediment to antitumor immunity (6) . TAM promiscuity in the TME, characterized by the up-regulation of inhibitory checkpoint molecules such as V domain immunoglobulin suppressor ofT cell activation (VISTA), SIGLEC1, and LILRB1 and the acquisition of an anti-inflammatory and protumor phenotype, serves as a longstanding challenge in achieving successful outcomes with ICT (7) . VISTA, expressed predominately by myeloid cells within the TME (8), therefore represents a potential candidate for bolstering  \n1department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, chicago, il, USA. 2department of chemistry, Northwestern University, evanston, il, USA. 3chan Zuckerberg Biohub chicago, chicago, il, USA. 4department of Biomedical engineering, Northwestern University, evanston, il, USA. 5department of Pharmaceutical Sciences, leslie dan Faculty of Pharmacy, University of toronto, toronto, Ontario, canada. 6department of electrical and computer engineering, University of toronto, toronto, Ontario, canada. 7terrence donnelly centre for cellular and Biomolecular Research, University of toronto, toronto, Ontario, canada. 8depar","cbCaiavTN6vEw3Eq","https://ap.wps.com/l/cbCaiavTN6vEw3Eq","pdf",2348449,15,"English","# Introduction\n## Immune checkpoint blockade and adaptive resistance\n## Tumor microenvironment and suppressive myeloid cells\n## VISTA as a regulatory target in myeloid-mediated resistance\n## Emerging VISTA-targeting strategies and remaining questions","[{\"question\":\"How does VISTA contribute to immune checkpoint blockade resistance in cancer?\",\"answer\":\"VISTA is expressed on myeloid cells in the tumor microenvironment and supports an anti-inflammatory, protumor phenotype, which impedes antitumor immune effector responses.\"},{\"question\":\"What approach was used to identify regulators of VISTA levels?\",\"answer\":\"A high-throughput microfluidic platform combined with a genome-wide CRISPR knockout screen was used to identify regulators controlling VISTA levels in macrophages.\"},{\"question\":\"What was the effect of targeting AhR and IRAK1 on tumor response?\",\"answer\":\"In mouse models, targeting both AhR and IRAK1 overcame resistance to immune checkpoint blockade and increased infiltration of cytotoxic CD8+ cells, natural killer cells, and antitumor macrophages.\"}]","Identification of VISTA regulators in macrophages mediating cancer cell survival | PDF",1790036990,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/54e053153b145e883d32400716d96ce6.webp",983,1250,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ce679281f7c3e3eb64e98fb18c11455c.webp",982,1249,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/384b228327049160ddc0af00ecb02a6e.webp",981,1248,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7d53f47ccc6dfb334d69dc81c875b377.webp",980,1247]